10.1021/bi201787p.s001 Ashwini K. Devkota Ashwini K. Devkota Clint D. J. Tavares Clint D. J. Tavares Mangalika Warthaka Mangalika Warthaka Olga Abramczyk Olga Abramczyk Kyle D. Marshall Kyle D. Marshall Tamer S. Kaoud Tamer S. Kaoud Kivanc Gorgulu Kivanc Gorgulu Bulent Ozpolat Bulent Ozpolat Kevin N. Dalby Kevin N. Dalby Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase by NH125: Evidence of a Common in Vitro Artifact American Chemical Society 2012 NH 125 exhibits kinase assay conditions NH 125 eEF 2 phosphorylation ATP kinase assay 549 lung cancer Elongation Factor 2 Kinase TRPM HEK Western blot approach IC 50 elongation factor 2 kinase ERK 2012-03-13 00:00:00 Journal contribution https://acs.figshare.com/articles/journal_contribution/Investigating_the_Kinetic_Mechanism_of_Inhibition_of_Elongation_Factor_2_Kinase_by_NH125_Evidence_of_a_Common_in_Vitro_Artifact/2541040 Evidence that elongation factor 2 kinase (eEF-2K) has potential as a target for anticancer therapy and possibly for the treatment of depression is emerging. Here the steady-state kinetic mechanism of eEF-2K is presented using a peptide substrate and is shown to conform to an ordered sequential mechanism with ATP binding first. Substrate inhibition by the peptide was observed and revealed to be competitive with ATP, explaining the observed ordered mechanism. Several small molecules are reported to inhibit eEF-2K activity with the most notable being the histidine kinase inhibitor NH125, which has been used in a number of studies to characterize eEF-2K activity in cells. While NH125 was previously reported to inhibit eEF-2K in vitro with an IC<sub>50</sub> of 60 nM, its mechanism of action was not established. Using the same kinetic assay, the ability of an authentic sample of NH125 to inhibit eEF-2K was assessed over a range of substrate and inhibitor concentrations. A typical dose–response curve for the inhibition of eEF-2K by NH125 is best fit to an IC<sub>50</sub> of 18 ± 0.25 μM and a Hill coefficient of 3.7 ± 0.14, suggesting that NH125 is a weak inhibitor of eEF-2K under the experimental conditions of a standard in vitro kinase assay. To test the possibility that NH125 is a potent inhibitor of eEF2 phosphorylation, we assessed its ability to inhibit the phosphorylation of eEF2. Under standard kinase assay conditions, NH125 exhibits a similar weak ability to inhibit the phosphorylation of eEF2 by eEF-2K. Notably, the activity of NH125 is severely abrogated by the addition of 0.1% Triton to the kinase assay through a process that can be reversed upon dilution. These studies suggest that NH125 is a nonspecific colloidal aggregator in vitro, a notion further supported by the observation that NH125 inhibits other protein kinases, such as ERK2 and TRPM7 in a manner similar to that of eEF-2K. As NH125 is reported to inhibit eEF-2K in a cellular environment, its ability to inhibit eEF2 phosphorylation was assessed in MDA-MB-231 breast cancer, A549 lung cancer, and HEK-293T cell lines using a Western blot approach. No sign of a decrease in the level of eEF2 phosphorylation was observed up to 12 h following addition of NH125 to the media. Furthermore, contrary to the previously reported literatures, NH125 induced the phosphorylation of eEF-2.